MENU About C. R. Bard, Inc. SHARE About C. R. Bard, Inc. For patients and healthcare professionals in wellness and prevention, early diagnosis, treatment, and post-care management. In fact, throughout our history, Bard has lead the industry in groundbreaking devices and therapies that continuously seek to set the new standard for excellence and quality. VIEW OUR HISTORICAL TIMELINE What drives us Our core values of Quality, Integrity, Service, and Innovation are central to how we work. Watch the videos to get to know a little more about us, our focus, and our history. About C. R. Bard, Inc. Global Website Directory Leadership Divisions & Locations Corporate Governance Mission & Values History Research & Development Meetings & Events Publications Social Responsibility Watch C. R. Bard, Inc. Corporate Video Our Mission To advance lives and the delivery of healthcare by profitably developing, manufacturing and marketing value-driven products which meet the quality, integrity, service, and innovation expectations of our customers while providing opportunities for our employees. As a result, we will optimize shareholder value and be a respected worldwide health care company. Watch C. R. Bard, Inc. Corporate Video A LONG HISTORY OF TECHNOLOGICAL INNOVATION 1900s 1920s 1930s 1940s 1950s 1960s 1970s 1980s 1990s 2000s 2010s 1907 Charles Russell Bard (pictured) was an American importer of French silks. In 1907, he begins importing Gomenol in New York City. 1907 Gomenol, a European cure-all, helped relieve Mr. Bard's urinary discomfort from tuberculosis. 1923 C. R. Bard, Inc. is formally incorporated. 1925 Bard publishes its first product catalog. 1926 Charles Russell Bard sells business to John F. Willits (pictured left), Sales Manager, and Edson L. Outwin (pictured right), Accountant, for $18,000. 1929 Harris L. Willits (pictured) joins the Bard staff as a sales representative. 1934 Company founder Charles Russell Bard dies. 1934 Davol Rubber Company of Providence, Rhode Island begins to manufacture the Foley catheter. Bard becomes the exclusive distributor for the Foley catheter and other Davol latex catheters. Pictured: The Davol Rubber Company in 1934, and an illustration accompanying Davol Rubber Company's 1935 patent application for a rubber catheter invented by Paul A. Raiche, an experimental engineer. 1940 Norman Jeckel develops the first American woven catheter and the machinery to manufacture it. He establishes the U.S. Catheter & Instrument Corporation (USCI) in Glens Falls, New York. Bard begins to distribute Jeckel's new catheter. 1945 Harris L. Willits becomes a member of the Board of Directors. 1948 Bard moves from New York City into a new building in Summit, New Jersey, and in 1949 the first Bard sales meeting is held at headquarters with representatives from Davol & USCI. 1954 Dr. DeBakey (pictured) develops the first arterial prosthesis. 1955 Harris L. Willits (pictured) is elected President of Bard. 1957 Bard celebrates its 50th anniversary, marking five decades of dedication to the medical profession. Pictured left to right: Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in December 1957. 1958 Bard introduces a pre-sterilized packaged Foley catheter and has a sterilizer built to start handling in-plant sterilization. Pictured: A 1958 Bardex Foley catheter advertisement explains how sterilized, packaged products can save customers time and money and also provide convenience since they are ready for instant use. 1961 Bard moves into a new one-story 50,000 square foot building in Murray Hill, New Jersey (pictured). The larger facility allowed the company to centralize its offices. 1961 Bard begins to extend its efforts beyond the urology market into cardiology, radiology and anesthesiology. Pictured: A Bard employee at the Glens Falls, New York, plant inspects coronary catheters produced by Bard's USCI Cardiology and Radiology Division. 1964 Bard establishes its first in-house manufacturing operation — producing the molding and assembling of medical plastic tubing. Pictured, left: Sterile and disposable medical supplies are stacked high at Bard's plant in Bridgewater, New Jersey, in the early 1960s. Pictured, right: The introduction of in-house sterilization operations in 1964 greatly expanded Bard’s manufacturing capabilities since laborsaving devices such as pre-sterilized hospital supplies had become a necessity rather than a luxury in the 1960s. 1965 Bard announces a 3-for-2 stock split. 1966 Harris L. Willits becomes Chairman of the Board. Roland F. Simons (pictured) is elected President. Simons was instrumental in increasing Bard's research and development programs throughout the 1960s. 1966 Bard and USCI merge, cementing a 25 year association. 1967 Bard builds a 100,000 square foot plant in Covington, Georgia, geographically expanding its manufacturing and warehousing operations. 1967 Bard announces a 2-for-1 stock split. 1968 J. Wendell Crain is elected President. 1968 Bard's capital stock is listed and traded on the New York Stock Exchange under the symbol "BCR". 1968 Bard builds a 172,000 square foot manufacturing plant at the Murray Hill, New Jersey location. Pictured: Technicians at Bard's New Jersey facilities subject samples of urological products to United States Pharmacopeia (USP) sterility testing, upholding the company's commitment to the highest product quality. 1971 Harris L. Willits is elected to honorary membership in the Medical Surgical Manufacturers Association, a distinction awarded only six other people. 1972 Bard joins with Kobayashi Pharmaceutical Company, Ltd. of Japan in establishing what is now known as Medicon, Inc., to import and market Bard products in Japan and form new joint ventures with international manufacturers. Pictured, left: Jay Bhatt, Bard's Japan manager in 1977, speaks at a USCI Division seminar in Tokyo, Japan. Pictured, right: With new leadership, Bard's Medicon unit saw fresh opportunities for business as Japan changed to diagnosis-based reimbursement. Indeed, sales grew by 27 percent in 2004. Pictured from left to right are K. Minato, Y. Sakai, and T. Kashiwagi. 1972 Bard announces a 2-for-1 stock split. 1975 Bard acquires the William Harvey Research Corporation, expanding cardiopulmonary products for open-heart and bypass surgery. Pictured: An inspector at the Santa Ana, California, plant examines components of William Harvey blood oxygenators used for cardiothoracic surgery. 1976 Robert H. McCaffrey is elected Director and President. 1978 Robert H. McCaffrey is elected Chairman of the Board and Chief Executive Officer. George T. Maloney is elected President and Chief Operating Officer. Pictured, from left to right: Over the years, Robert McCaffrey, Harris Willits, and George Maloney developed a friendly corporate culture, which many Bard employees welcomed with gratitude. 1978 Harris L. Willits is elected Honorary Chairman. 1979 Bard obtains the exclusive rights to manufacture and market the Gruntzig catheter, a balloon-tipped angioplasty catheter giving surgeons a safer and less costly alternative to open-heart surgery. Pictured: Using one of Bard's USCI catheter systems, a doctor prepares for an angioplasty procedure in a catheterization laboratory. 1980 After a 46-year association, Bard acquires Davol Inc. (pictured), with its Foley catheter manufacturing facilities in Moncks Corner, South Carolina and Clacton-On-Sea, England. 1982 Bard announces a 3-for-2 stock split. 1984 Bard sets up manufacturing plant in Nogales, Mexico. 1984 Bard acquires Evermed, creating the platform for the Bard Access Systems franchise. 1985 A joint venture, Bard Bio-Spectrum Pty. Ltd., is created in Australia. 1986 Bard announces a 2-for-1 stock split. 1988 Bard Europe is formed by merging Bard UK/Europe with USCI International. Pictured, left: A cardiologist in the laboratory of Policlinico Umberto in Rome, Italy, examines Bard Simplus and Probe angioplasty catheters in 1988. Courtesy of John Zoiner Photography. Pictured, right: The headquarters of Laboratories Bard in the Paris suburb of Gentilly, France. 1988 Bard's 1985 Management Executive Committee guided the company's divisions to operate as entrepreneurial units and remain organized around market specialization. Pictured from left to right, standing: Edward A. Leskanic, David W. Prigmore, and Laurence E. Lindars. Seated: George A. Davis, William G. Little, Terence C. Brady Jr., George T. Maloney, and Robert H. McCaffrey. Courtesy of Bill Ray Photography. 1989 George T. Maloney (pictured, greeting visitors at Bard’s annual meeting) is elected President and Chief Executive Officer. His friendly and personable nature, as well as his problem-solving skills and sharp mind, earned him a solid reputation for more than three decades with the company. 1989 Bard acquires Catheter Technology Corporation, Salt Lake City, Utah, strengthening Bard's position in the vascular access devices market. This becomes the divisional headquarters for Bard Access Systems, Inc. in 1991. Pictured: An I.V. nurse at Christ Hospital in Cincinnati, Ohio, discusses catheter placement at a patient's bedside with Bard Access Systems employees. 1991 Bard Electrophysiology Division is formed. 1991 George T. Maloney (pictured) is elected Chairman of the Board and Chief Executive Officer. 1992 Bard Bio-Spectrum Pty. Ltd. becomes Bard Australia. 1992 Harris L. Willits, Honorary Chairman, dies. 1994 William Longfield (pictured) is elected President and Chief Executive Officer. 1994 Bard acquires Angiomed AG (biliary stent). 1994 Corporate Healthcare Services organization is established. 1995 William Longfield is elected Chairman of the Board. 1996 Bard acquires IMPRA, Inc. (vascular prosthetics). 1996 Bard Medical Division is formed. Pictured, left: Bard FiberOptic Technologies in Ann Arbor, Michigan, which manufactured high-tech urological monitoring devices using fiber optics, added to the company's technological revolution in the late 1990s. Here, quality assurance auditor Donna Reese performs an inspection. Pictured, right: The BARDEX® Lubricath Foley catheter is a late 1990s update of the Foley catheter, Bard's trademark product. 1996 Bard enters joint venture agreement with Pacific Healthcare in Taiwan. Bard opens sales offices in China, Korea and Singapore. Pictured: At Bard, new product development and incremental product improvement is a continuous process. Bard employee Hong le Nguyen conducts flow tests on PDLC. 1998 Bard divests USCI cardiology division, cardiac assist & cardiopulmonary business units. 1999 Bard acquires Dymax Inc. an ultrasound technology for placing catheters. The 1994 Vas-Cath acquisition helped Bard expand its dialysis catheter and peripheral balloon angioplasty catheter product lines. Pictured: Bard employee Lena Diaz assembles the rod for a dual lumen wing retainer. 2000 Bard acquires the assets of Surgical Sense, Inc. and its Kugel® patch product line. 2003 Timothy M. Ring (pictured, left) is elected Chairman of the Board and Chief Executive Officer. John Weiland (pictured, right) is elected President and Chief Operating Officer. Both were groomed by predecessor William Longfield to continue growing Bard in the 21st century. In their first full year running the company, net sales grew by 13 percent in constant currency. Courtesy of Gloria Baker Photography. 2003 Bard Peripheral Vascular subsidiary is formed. Pictured top: Luminexx™ vascular stent 2003 Bard acquires vacuum-assisted biopsy device technology from Biomedical Instruments and Products GmbH. 2003 Bard acquires SourceTech Medical, L.L.C., an iodine radioactive isotope seed business for Brachytherapy. Pictured: Hunter Herndon, of Midlothian, Virginia, buffs the wheel of his vintage 1934 Ford Coupe. Herndon was able to quickly return to his normal activities after undergoing treatment for prostate cancer with Bard's ProSeed® Brachytherapy service, which places tiny radioactive seeds guided by ultrasound into the prostate gland. Courtesy of Gloria Baker Photography. 2004 Bard acquires assets of ONUX Medical and its Salute® fixation system for hernia and soft tissue repair. 2004 Bard announces 2-for-1 stock split. In 2003, Bard's worldwide operations team spearheaded improvements that increased profit margins by 3.2 percentage points. Pictured clockwise from top left are Mark Walaska, staff vice president of manufacturing; Frank Maloit, staff vice president for corporate procurement; Scott Mummert, director for operational excellence; Kevin Phoenix, director of facilities; John Moran, staff vice president for manufacturing projects; Ted Doorley, staff vice president for manufacturing; and Joe Cherry, vice president of operations. Courtesy of Gloria Baker Photography. 2005 Bard acquires assets of Genyx Medical, including the TegressT™ implantable bulking agent for the treatment of stress urinary incontinence. 2006 Bard acquires Venetec International, Inc., manufacturer of the StatLock® line of catheter securement devices. 2007 Bard celebrates 100 year milestone. 2008 Bard acquires LifeStent® (pictured) from Edwards Lifesciences which is marketed by Bard’s Peripheral Vascular Division, Tempe Arizona. 2009 Bard receives FDA PMA approval of LifeStent® for SFA (superficial femoral arteries) indication. 2010 In the largest acquisition to date, Bard acquires SenoRx, Inc., providing Bard leadership products across all breast biopsy and marker segments. 2011 Bard acquires Medivance, Inc., the market leader in the field of therapeutic hypothermia. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner. 2011 Bard acquires Lutonix, Inc., developer of a drug-coated percutaneous transluminal angioplasty (PTA) balloon. Lutonix is the first to conduct the only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease. 2012 Bard acquires privately-held Neomend, Inc., a leading developer and supplier of sprayable surgical sealants and anti-adhesion products. This merger significantly expands the business opportunities for Bard surgical specialties in the Davol subsidiary. 2013 Bard Acquires Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. Medafor’s Arista® MPH Hemostat, is indicated as an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical. The acquisition expands the business opportunities for Bard’s surgical specialties in its Davol subsidiary. 2013 Bard divests Electrophysiology business and sells certain assets to Boston Scientific Corporation. 2013 Bard acquires Rochester Medical, Inc., a leading developer and supplier of silicone urinary incontinence and urine drainage products. The merger represents a compelling strategic fit that enhances Bard’s position in the global urology homecare market. 2014 The Lutonix® 035 Drug Coated Balloon is the first FDA-Approved Drug Coated Balloon available in the U.S. for the treatment of Femoropopliteal Occlusive Disease. The Lutonix® 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries. 2014 XENMATRIX™ AB Surgical Graft Antibacterial-Coated Regenerative Collagen Matrix is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the graft colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2 It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair. 1. IMS Data, Q2 2014, 550K search, fda.gov. 2. Preclinical data on file; results may not correlate to clinical performance. 2015 Bard acquires full ownership of its joint venture, Medicon, Inc., in Japan. 2016 Bard acquires Liberator Medical Holdings, Inc. Liberator is a direct-to-consumer distributor of medical products classified as Durable Medical Equipment (DME). Stock Quote BCR: 320.83 Change: -0.05 Volume Traded: 340,050 As of 8/15/2017 7:25:41 PM (20 Minutes Delay Minimum) See Details > Advancing Lives and the Delivery of Health Care™ CORP 17-22 Copyright © 2017 C. R. Bard, Inc. All Rights Reserved. Terms of Use | Privacy Policy